{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T10:39:41Z","timestamp":1781779181646,"version":"3.54.5"},"reference-count":98,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,2,28]],"date-time":"2024-02-28T00:00:00Z","timestamp":1709078400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,2,28]],"date-time":"2024-02-28T00:00:00Z","timestamp":1709078400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100017594","name":"Medical Science and Technology Project of Zhejiang Province","doi-asserted-by":"publisher","award":["2021KY1137"],"award-info":[{"award-number":["2021KY1137"]}],"id":[{"id":"10.13039\/501100017594","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017594","name":"Medical Science and Technology Project of Zhejiang Province","doi-asserted-by":"publisher","award":["2023RC290"],"award-info":[{"award-number":["2023RC290"]}],"id":[{"id":"10.13039\/501100017594","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Neurol Belg"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1007\/s13760-024-02493-1","type":"journal-article","created":{"date-parts":[[2024,2,28]],"date-time":"2024-02-28T03:02:27Z","timestamp":1709089347000},"page":"1213-1223","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["A review of type 3 Gaucher disease: unique neurological manifestations and advances in treatment"],"prefix":"10.1007","volume":"124","author":[{"given":"Wei","family":"Zhong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Fei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0578-919X","authenticated-orcid":false,"given":"Pan","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,28]]},"reference":[{"key":"2493_CR1","doi-asserted-by":"publisher","first-page":"511","DOI":"10.3109\/07853890.2013.849003","volume":"45","author":"MS Beavan","year":"2013","unstructured":"Beavan MS, Schapira AHV (2013) Glucocerebrosidase mutations and the pathogenesis of Parkinson disease. Ann Med 45:511\u2013521. https:\/\/doi.org\/10.3109\/07853890.2013.849003","journal-title":"Ann Med"},{"key":"2493_CR2","doi-asserted-by":"publisher","first-page":"S12","DOI":"10.1002\/ajh.24063","volume":"90","author":"GA Grabowski","year":"2015","unstructured":"Grabowski GA, Zimran A, Ida H (2015) Gaucher disease types 1 and 3: phenotypic characterization of large populations from the ICGG gaucher registry. Am J Hematol 90:S12\u2013S18. https:\/\/doi.org\/10.1002\/ajh.24063","journal-title":"Am J Hematol"},{"key":"2493_CR3","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1016\/s0140-6736(08)61522-6","volume":"372","author":"GA Grabowski","year":"2008","unstructured":"Grabowski GA (2008) Phenotype, diagnosis, and treatment of Gaucher\u2019s disease. Lancet 372:1263\u20131271. https:\/\/doi.org\/10.1016\/s0140-6736(08)61522-6","journal-title":"Lancet"},{"key":"2493_CR4","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1080\/17446651.2018.1445524","volume":"13","author":"SE Gary","year":"2018","unstructured":"Gary SE, Ryan E, Steward AM, Sidransky E (2018) Recent advances in the diagnosis and management of Gaucher disease. Expert Rev Endocrinol Metab 13:107\u2013118. https:\/\/doi.org\/10.1080\/17446651.2018.1445524","journal-title":"Expert Rev Endocrinol Metab"},{"key":"2493_CR5","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1067\/s0022-3476(03)00302-0","volume":"143","author":"O Goker-Alpan","year":"2003","unstructured":"Goker-Alpan O, Schiffmann R, Park JK et al (2003) Phenotypic continuum in neuronopathic Gaucher disease: an intermediate phenotype between type 2 and type 3. J Pediatr 143:273\u2013276. https:\/\/doi.org\/10.1067\/s0022-3476(03)00302-0","journal-title":"J Pediatr"},{"key":"2493_CR6","doi-asserted-by":"publisher","first-page":"e2119","DOI":"10.1212\/wnl.0000000000010605","volume":"95","author":"TR Lal","year":"2020","unstructured":"Lal TR, Seehra GK, Steward AM et al (2020) The natural history of type 2 Gaucher disease in the 21st century. Neurology 95:e2119\u2013e2130. https:\/\/doi.org\/10.1212\/wnl.0000000000010605","journal-title":"Neurology"},{"key":"2493_CR7","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.ymgmr.2017.10.011","volume":"14","author":"IVD Schwartz","year":"2018","unstructured":"Schwartz IVD, G\u00f6ker-Alpan \u00d6, Kishnani PS et al (2018) Characteristics of 26 patients with type 3 Gaucher disease: a descriptive analysis from the Gaucher outcome survey. Mol Genet Metab Rep 14:73\u201379. https:\/\/doi.org\/10.1016\/j.ymgmr.2017.10.011","journal-title":"Mol Genet Metab Rep"},{"key":"2493_CR8","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1136\/bjophthalmol-2018-312846","volume":"103","author":"AW Winter","year":"2019","unstructured":"Winter AW, Salimi A, Ospina LH, Roos JCP (2019) Ophthalmic manifestations of Gaucher disease: the most common lysosomal storage disorder. Br J Ophthalmol 103:315\u2013326. https:\/\/doi.org\/10.1136\/bjophthalmol-2018-312846","journal-title":"Br J Ophthalmol"},{"key":"2493_CR9","doi-asserted-by":"publisher","first-page":"85","DOI":"10.3390\/jcm12010085","volume":"12","author":"G Castillon","year":"2022","unstructured":"Castillon G, Chang S-C, Moride Y (2022) Global incidence and prevalence of Gaucher disease: a targeted literature review. J Clin Med 12:85. https:\/\/doi.org\/10.3390\/jcm12010085","journal-title":"J Clin Med"},{"key":"2493_CR10","first-page":"416","volume":"70","author":"Y Nguyen","year":"2020","unstructured":"Nguyen Y, Stirnemann J, Belmatoug N (2020) Maladie de Gaucher. Rev Prat 70:416\u2013420","journal-title":"Rev Prat"},{"key":"2493_CR11","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.ymgme.2022.03.001","volume":"136","author":"NJ Weinreb","year":"2022","unstructured":"Weinreb NJ, Goker-Alpan O, Kishnani PS et al (2022) The diagnosis and management of Gaucher disease in pediatric patients: where do we go from here? Mol Genet Metab 136:4\u201321. https:\/\/doi.org\/10.1016\/j.ymgme.2022.03.001","journal-title":"Mol Genet Metab"},{"key":"2493_CR12","doi-asserted-by":"publisher","first-page":"364","DOI":"10.3390\/cells8040364","volume":"8","author":"GM Riboldi","year":"2019","unstructured":"Riboldi GM, Fonzo ABD (2019) GBA, Gaucher disease, and Parkinson\u2019s disease: from genetic to clinic to new therapeutic approaches. Cells 8:364. https:\/\/doi.org\/10.3390\/cells8040364","journal-title":"Cells"},{"key":"2493_CR13","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1002\/ajh.21362","volume":"84","author":"TH Taddei","year":"2009","unstructured":"Taddei TH, Kacena KA, Yang M et al (2009) The underrecognized progressive nature of N370S Gaucher disease and assessment of cancer risk in 403 patients. Am J Hemat 84:208\u2013214. https:\/\/doi.org\/10.1002\/ajh.21362","journal-title":"Am J Hemat"},{"key":"2493_CR14","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.ymgme.2009.05.001","volume":"97","author":"A Tajima","year":"2009","unstructured":"Tajima A, Yokoi T, Ariga M et al (2009) Clinical and genetic study of Japanese patients with type 3 Gaucher disease. Mol Genet Metab 97:272\u2013277. https:\/\/doi.org\/10.1016\/j.ymgme.2009.05.001","journal-title":"Mol Genet Metab"},{"key":"2493_CR15","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.bcmd.2010.07.010","volume":"46","author":"S-Y Jeong","year":"2011","unstructured":"Jeong S-Y, Park S-J, Kim HJ (2011) Clinical and genetic characteristics of Korean patients with Gaucher disease. Blood Cells Mol Dis 46:11\u201314. https:\/\/doi.org\/10.1016\/j.bcmd.2010.07.010","journal-title":"Blood Cells Mol Dis"},{"key":"2493_CR16","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1007\/s12519-011-0309-1","volume":"7","author":"Z El-Morsy","year":"2011","unstructured":"El-Morsy Z, Khashaba MT, Soliman OE-S et al (2011) Glucosidase acid beta gene mutations in Egyptian children with Gaucher disease and relation to disease phenotypes. World J Pediatr 7:326\u2013330. https:\/\/doi.org\/10.1007\/s12519-011-0309-1","journal-title":"World J Pediatr"},{"key":"2493_CR17","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.bcmd.2006.11.003","volume":"38","author":"FYM Choy","year":"2007","unstructured":"Choy FYM, Zhang W, Shi H-P et al (2007) Gaucher disease among Chinese patients: review on genotype\/phenotype correlation from 29 patients and identification of novel and rare alleles. Blood Cells Mol Dis 38:287\u2013293. https:\/\/doi.org\/10.1016\/j.bcmd.2006.11.003","journal-title":"Blood Cells Mol Dis"},{"key":"2493_CR18","doi-asserted-by":"publisher","first-page":"e55","DOI":"10.1212\/nxg.0000000000000055","volume":"2","author":"M Abdelwahab","year":"2016","unstructured":"Abdelwahab M, Blankenship D, Schiffmann R (2016) Long-term follow-up and sudden unexpected death in Gaucher disease type 3 in Egypt. Neurol Genet 2:e55. https:\/\/doi.org\/10.1212\/nxg.0000000000000055","journal-title":"Neurol Genet"},{"key":"2493_CR19","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1177\/1060028013500469","volume":"47","author":"LL Bennett","year":"2013","unstructured":"Bennett LL, Mohan D (2013) Gaucher disease and its treatment options. Ann Pharmacother 47:1182\u20131193. https:\/\/doi.org\/10.1177\/1060028013500469","journal-title":"Ann Pharmacother"},{"key":"2493_CR20","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1002\/ajh.21888","volume":"86","author":"PK Mistry","year":"2010","unstructured":"Mistry PK, Cappellini MD, Lukina E et al (2010) A reappraisal of Gaucher disease-diagnosis and disease management algorithms. Am J Hematol 86:110\u2013115. https:\/\/doi.org\/10.1002\/ajh.21888","journal-title":"Am J Hematol"},{"key":"2493_CR21","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1016\/s0002-9149(84)80115-0","volume":"54","author":"A Casta","year":"1984","unstructured":"Casta A, Hayden K, Wolf WJ (1984) Calcification of the ascending aorta and aortic and mitral valves in Gaucher\u2019s disease. Am J Cardiol 54:1390\u20131391. https:\/\/doi.org\/10.1016\/s0002-9149(84)80115-0","journal-title":"Am J Cardiol"},{"key":"2493_CR22","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.ymgme.2019.05.011","volume":"127","author":"A Kurolap","year":"2019","unstructured":"Kurolap A, del Toro M, Spiegel R et al (2019) Gaucher disease type 3c: new patients with unique presentations and review of the literature. Mol Genet Metab 127:138\u2013146. https:\/\/doi.org\/10.1016\/j.ymgme.2019.05.011","journal-title":"Mol Genet Metab"},{"key":"2493_CR23","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1001\/archinte.158.16.1754","volume":"158","author":"J Charrow","year":"1998","unstructured":"Charrow J, Esplin JA, Gribble TJ et al (1998) Gaucher disease. Arch Intern Med 158:1754. https:\/\/doi.org\/10.1001\/archinte.158.16.1754","journal-title":"Arch Intern Med"},{"key":"2493_CR24","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1038\/s10038-018-0438-7","volume":"63","author":"K Momosaki","year":"2018","unstructured":"Momosaki K, Kido J, Matsumoto S et al (2018) High-risk screening for Gaucher disease in patients with neurological symptoms. J Hum Genet 63:717\u2013721. https:\/\/doi.org\/10.1038\/s10038-018-0438-7","journal-title":"J Hum Genet"},{"key":"2493_CR25","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/0888-7543(89)90319-4","volume":"4","author":"M Horowitz","year":"1989","unstructured":"Horowitz M, Wilder S, Horowitz Z et al (1989) The human glucocerebrosidase gene and pseudogene: structure and evolution. Genomics 4:87\u201396. https:\/\/doi.org\/10.1016\/0888-7543(89)90319-4","journal-title":"Genomics"},{"key":"2493_CR26","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-020-01597-0","author":"Y-M Kim","year":"2020","unstructured":"Kim Y-M, Choi J-H, Kim G-H et al (2020) The GBA p.G85E mutation in Korean patients with non-neuronopathic Gaucher disease: founder and neuroprotective effects. Orphanet J Rare Dis. https:\/\/doi.org\/10.1186\/s13023-020-01597-0","journal-title":"Orphanet J Rare Dis"},{"key":"2493_CR27","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1001\/archneur.64.7.1056","volume":"64","author":"E-K Tan","year":"2007","unstructured":"Tan E-K, Tong J, Fook-Chong S et al (2007) Glucocerebrosidase mutations and risk of Parkinson disease in Chinese patients. Arch Neurol 64:1056. https:\/\/doi.org\/10.1001\/archneur.64.7.1056","journal-title":"Arch Neurol"},{"key":"2493_CR28","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/j.bcmd.2006.02.001","volume":"36","author":"L Wan","year":"2006","unstructured":"Wan L, Hsu C-M, Tsai C-H et al (2006) Mutation analysis of Gaucher disease patients in Taiwan: high prevalence of the RecNciI and L444P mutations. Blood Cells Mol Dis 36:422\u2013425. https:\/\/doi.org\/10.1016\/j.bcmd.2006.02.001","journal-title":"Blood Cells Mol Dis"},{"key":"2493_CR29","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1002\/humu.20676","volume":"29","author":"KS Hruska","year":"2008","unstructured":"Hruska KS, LaMarca ME, Scott CR, Sidransky E (2008) Gaucher disease: mutation and polymorphism spectrum in the glucocerebrosidase gene (GBA). Hum Mutat 29:567\u2013583. https:\/\/doi.org\/10.1002\/humu.20676","journal-title":"Hum Mutat"},{"key":"2493_CR30","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1086\/302925","volume":"66","author":"V Koprivica","year":"2000","unstructured":"Koprivica V, Stone DL, Park JK et al (2000) Analysis and classification of 304 mutant alleles in patients with type 1 and type 3 Gaucher disease. Am J Hum Genet 66:1777\u20131786. https:\/\/doi.org\/10.1086\/302925","journal-title":"Am J Hum Genet"},{"key":"2493_CR31","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.ymgme.2016.11.006","volume":"120","author":"PK Mistry","year":"2017","unstructured":"Mistry PK, Lopez G, Schiffmann R et al (2017) Gaucher disease: progress and ongoing challenges. Mol Genet Metab 120:8\u201321. https:\/\/doi.org\/10.1016\/j.ymgme.2016.11.006","journal-title":"Mol Genet Metab"},{"key":"2493_CR32","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.bcmd.2010.10.007","volume":"46","author":"M Biegstraaten","year":"2011","unstructured":"Biegstraaten M, van Schaik IN, Aerts JMFG et al (2011) A monozygotic twin pair with highly discordant Gaucher phenotypes. Blood Cells Mol Dis 46:39\u201341. https:\/\/doi.org\/10.1016\/j.bcmd.2010.10.007","journal-title":"Blood Cells Mol Dis"},{"key":"2493_CR33","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1016\/j.arcmed.2021.05.001","volume":"52","author":"RS Garc\u00eda","year":"2021","unstructured":"Garc\u00eda RS, de Frutos LL, Arreguin E\u00c1 et al (2021) Gaucher disease: identification and novel variants in Mexican and Spanish patients. Arch M\u00e9d Res 52:731\u2013737. https:\/\/doi.org\/10.1016\/j.arcmed.2021.05.001","journal-title":"Arch M\u00e9d Res"},{"key":"2493_CR34","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.ymgme.2021.01.002","volume":"132","author":"EC Daykin","year":"2021","unstructured":"Daykin EC, Ryan E, Sidransky E (2021) Diagnosing neuronopathic Gaucher disease: new considerations and challenges in assigning Gaucher phenotypes. Mol Genet Metab 132:49\u201358. https:\/\/doi.org\/10.1016\/j.ymgme.2021.01.002","journal-title":"Mol Genet Metab"},{"key":"2493_CR35","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1111\/j.1651-2227.2007.00641.x","volume":"97","author":"JM Aerts","year":"2008","unstructured":"Aerts JM, van Breemen MJ, Bussink AP et al (2008) Biomarkers for lysosomal storage disorders: identification and application as exemplified by chitotriosidase in Gaucher disease. Acta Paediatr 97:7\u201314. https:\/\/doi.org\/10.1111\/j.1651-2227.2007.00641.x","journal-title":"Acta Paediatr"},{"key":"2493_CR36","doi-asserted-by":"publisher","first-page":"e79732","DOI":"10.1371\/journal.pone.0079732","volume":"8","author":"A Rolfs","year":"2013","unstructured":"Rolfs A, Giese A-K, Grittner U et al (2013) Glucosylsphingosine is a highly sensitive and specific biomarker for primary diagnostic and follow-up monitoring in Gaucher disease in a non-jewish, Caucasian cohort of Gaucher disease patients. PLoS ONE 8:e79732. https:\/\/doi.org\/10.1371\/journal.pone.0079732","journal-title":"PLoS ONE"},{"key":"2493_CR37","doi-asserted-by":"publisher","first-page":"e118","DOI":"10.1182\/blood-2011-05-352971","volume":"118","author":"N Dekker","year":"2011","unstructured":"Dekker N, van Dussen L, Hollak CEM et al (2011) Elevated plasma glucosylsphingosine in Gaucher disease: relation to phenotype, storage cell markers, and therapeutic response. Blood 118:e118\u2013e127. https:\/\/doi.org\/10.1182\/blood-2011-05-352971","journal-title":"Blood"},{"key":"2493_CR38","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1002\/jimd.12192","volume":"43","author":"JT Saville","year":"2019","unstructured":"Saville JT, McDermott BK, Chin SJ et al (2019) Expanding the clinical utility of glucosylsphingosine for Gaucher disease. J Inherit Metab Dis 43:558\u2013563. https:\/\/doi.org\/10.1002\/jimd.12192","journal-title":"J Inherit Metab Dis"},{"key":"2493_CR39","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1002\/acn3.292","volume":"3","author":"A Narita","year":"2016","unstructured":"Narita A, Shirai K, Itamura S et al (2016) Ambroxol chaperone therapy for neuronopathic Gaucher disease: a pilot study. Ann Clin Transl Neurol 3:200\u2013215. https:\/\/doi.org\/10.1002\/acn3.292","journal-title":"Ann Clin Transl Neurol"},{"key":"2493_CR40","doi-asserted-by":"publisher","first-page":"S130","DOI":"10.1016\/j.ymgme.2018.12.334","volume":"126","author":"K Savostyanov","year":"2019","unstructured":"Savostyanov K, Pushkov A, Mura\u2019vova L, et al (2019) Glucosylfingosine (Lyso-GL1) may be the primary biomarker for screening Gaucher disease in Russian patients. Mol Genet Metab 126:S130. https:\/\/doi.org\/10.1016\/j.ymgme.2018.12.334","journal-title":"Mol Genet Metab"},{"key":"2493_CR41","doi-asserted-by":"publisher","first-page":"3033","DOI":"10.3390\/ijms20123033","volume":"20","author":"N Hurvitz","year":"2019","unstructured":"Hurvitz N, Dinur T, Becker-Cohen M et al (2019) Glucosylsphingosine (lyso-Gb1) as a biomarker for monitoring treated and untreated children with Gaucher disease. International J Of Molecular Sciences 20:3033. https:\/\/doi.org\/10.3390\/ijms20123033","journal-title":"International J Of Molecular Sciences"},{"key":"2493_CR42","doi-asserted-by":"publisher","first-page":"S183","DOI":"10.3233\/jpd-212739","volume":"11","author":"A Abeliovich","year":"2021","unstructured":"Abeliovich A, Hefti F, Sevigny J (2021) Gene therapy for Parkinson\u2019s disease associated with GBA1 mutations. J Parkinson\u2019s Dis 11:S183\u2013S188. https:\/\/doi.org\/10.3233\/jpd-212739","journal-title":"J Parkinson\u2019s Dis"},{"key":"2493_CR43","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1007\/s10545-009-9009-6","volume":"33","author":"A Tylki-Szyma\u0144ska","year":"2010","unstructured":"Tylki-Szyma\u0144ska A, Vellodi A, El-Beshlawy A et al (2010) Neuronopathic Gaucher disease: demographic and clinical features of 131 patients enrolled in the international collaborative gaucher group neurological outcomes subregistry. J Inherit Metab Dis 33:339\u2013346. https:\/\/doi.org\/10.1007\/s10545-009-9009-6","journal-title":"J Inherit Metab Dis"},{"key":"2493_CR44","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.braindev.2010.02.005","volume":"33","author":"I Kraoua","year":"2011","unstructured":"Kraoua I, Sedel F, Caillaud C et al (2011) A french experience of type 3 Gaucher disease: phenotypic tdersity and neurological outcome of 10 patients. Brain Develop 33:131\u2013139. https:\/\/doi.org\/10.1016\/j.braindev.2010.02.005","journal-title":"Brain Develop"},{"key":"2493_CR45","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1196\/annals.1325.054","volume":"1039","author":"AP Accardo","year":"2005","unstructured":"Accardo AP, Pensiero S, Perissutti P (2005) Saccadic analysis for early identification of neurological involvement in Gaucher disease. Ann N Y Acad Sci 1039:503\u2013507. https:\/\/doi.org\/10.1196\/annals.1325.054","journal-title":"Ann N Y Acad Sci"},{"key":"2493_CR46","doi-asserted-by":"publisher","first-page":"e22410","DOI":"10.1371\/journal.pone.0022410","volume":"6","author":"W Benko","year":"2011","unstructured":"Benko W, Ries M, Wiggs EA et al (2011) The saccadic and neurological deficits in type 3 Gaucher disease. PLoS\u00a0One 6:e22410. https:\/\/doi.org\/10.1371\/journal.pone.0022410","journal-title":"PLoS\u00a0One"},{"key":"2493_CR47","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-019-1244-9","author":"S Hopf","year":"2019","unstructured":"Hopf S, Pfeiffer N, Liesenfeld M et al (2019) A comprehensive monocentric ophthalmic study with Gaucher disease type 3 patients: vitreoretinal lesions, retinal atrophy and characterization of abnormal saccades. Orphanet J Rare Dis. https:\/\/doi.org\/10.1186\/s13023-019-1244-9","journal-title":"Orphanet J Rare Dis"},{"key":"2493_CR48","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1212\/wnl.43.10.1993","volume":"43","author":"MC Patterson","year":"1993","unstructured":"Patterson MC, Horowitz M, Abel RB et al (1993) Isolated horizontal supranuclear gaze palsy as a marker of severe systemic involvement in Gaucher\u2019s disease. Neurology 43:1993\u20131993. https:\/\/doi.org\/10.1212\/wnl.43.10.1993","journal-title":"Neurology"},{"key":"2493_CR49","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1002\/ana.21491","volume":"64","author":"R Schiffmann","year":"2008","unstructured":"Schiffmann R, FitzGibbon EJ, Harris C et al (2008) Randomized, controlled trial of miglustat in Gaucher\u2019s disease type 3. Ann Neurol 64:514\u2013522. https:\/\/doi.org\/10.1002\/ana.21491","journal-title":"Ann Neurol"},{"key":"2493_CR50","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1080\/13816810.2016.1193878","volume":"38","author":"A Watanabe","year":"2016","unstructured":"Watanabe A, Gekka T, Arai K, Tsuneoka H (2016) A case of traction retinal detachment in a patient with Gaucher disease. Ophthalmic Genet 38:273\u2013276. https:\/\/doi.org\/10.1080\/13816810.2016.1193878","journal-title":"Ophthalmic Genet"},{"key":"2493_CR51","doi-asserted-by":"publisher","first-page":"E26","DOI":"10.1002\/clc.20348","volume":"33","author":"N Cindik","year":"2009","unstructured":"Cindik N, Ozcay F, S\u00fcren D et al (2009) Gaucher disease with communicating hydrocephalus and cardiac involvement. Clin Cardiol 33:E26\u2013E30. https:\/\/doi.org\/10.1002\/clc.20348","journal-title":"Clin Cardiol"},{"key":"2493_CR52","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1016\/s0002-9394(98)00249-9","volume":"126","author":"A Guemes","year":"1998","unstructured":"Guemes A, Kosmorsky GS, Moodie DS et al (1998) Corneal opacities in gaucher disease. Am J Ophthalmol 126:833\u2013835. https:\/\/doi.org\/10.1016\/s0002-9394(98)00249-9","journal-title":"Am J Ophthalmol"},{"key":"2493_CR53","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1007\/s00417-021-05424-5","volume":"260","author":"S Hopf","year":"2021","unstructured":"Hopf S, Schuster AK, Hennermann JB et al (2021) Retinal thinning in phenylketonuria and Gaucher disease type 3. Graefe\u2019s Arch Clin Exp Ophthalmol 260:1153\u20131160. https:\/\/doi.org\/10.1007\/s00417-021-05424-5","journal-title":"Graefe\u2019s Arch Clin Exp Ophthalmol"},{"key":"2493_CR54","doi-asserted-by":"publisher","DOI":"10.18240\/ijo.2018.09.23","author":"T-T Zhao","year":"2018","unstructured":"Zhao T-T, Li H-L, Guo X-J et al (2018) Retinal detachment in a boy with Gaucher disease. Int J Ophthalmol. https:\/\/doi.org\/10.18240\/ijo.2018.09.23","journal-title":"Int J Ophthalmol"},{"key":"2493_CR55","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1212\/01.wnl.0000130191.31669.48","volume":"63","author":"PE Campbell","year":"2004","unstructured":"Campbell PE, Harris CM, Vellodi A (2004) Deterioration of the auditory brainstem response in children with type 3 Gaucher disease. Neurology 63:385\u2013387. https:\/\/doi.org\/10.1212\/01.wnl.0000130191.31669.48","journal-title":"Neurology"},{"key":"2493_CR56","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1055\/s-2001-16611","volume":"32","author":"D-E Bamiou","year":"2001","unstructured":"Bamiou D-E, Campbell P, Liasis A et al (2001) Audiometric abnormalities in children with Gaucher disease type 3. Neuropediatrics 32:136\u2013141. https:\/\/doi.org\/10.1055\/s-2001-16611","journal-title":"Neuropediatrics"},{"key":"2493_CR57","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1002\/(sici)1098-1004(200002)15:2<181::aid-humu7>3.0.co;2-s","volume":"15","author":"DL Stone","year":"2000","unstructured":"Stone DL, Tayebi N, Orvisky E et al (2000) Glucocerebrosidase gene mutations in patients with type 2 Gaucher disease. Hum Mutat 15:181\u2013188. https:\/\/doi.org\/10.1002\/(sici)1098-1004(200002)15:2%3c181::aid-humu7%3e3.0.co;2-s","journal-title":"Hum Mutat"},{"key":"2493_CR58","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1203\/00006450-199805000-00003","volume":"43","author":"N Tayebi","year":"1998","unstructured":"Tayebi N, Reissner KJ, Lau EK et al (1998) Genotypic heterogeneity and phenotypic variation among patients with type 2 Gaucher\u2019s disease. Pediatr Res 43:571\u2013578. https:\/\/doi.org\/10.1203\/00006450-199805000-00003","journal-title":"Pediatr Res"},{"key":"2493_CR59","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1212\/wnl.57.10.1793","volume":"57","author":"P Manganotti","year":"2001","unstructured":"Manganotti P, Tamburin S, Zanette G, Fiaschi A (2001) Hyperexcitable cortical responses in progressive myoclonic epilepsy: a TMS study. Neurology 57:1793\u20131799. https:\/\/doi.org\/10.1212\/wnl.57.10.1793","journal-title":"Neurology"},{"key":"2493_CR60","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1203\/01.pdr.0000049515.79882.94","volume":"53","author":"JK Park","year":"2003","unstructured":"Park JK, Orvisky E, Tayebi N et al (2003) Myoclonic epilepsy in Gaucher disease: genotype-phenotype insights from a rare patient subgroup. Pediatr Res 53:387\u2013395. https:\/\/doi.org\/10.1203\/01.pdr.0000049515.79882.94","journal-title":"Pediatr Res"},{"key":"2493_CR61","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.bcmd.2016.10.011","volume":"68","author":"M Machaczka","year":"2018","unstructured":"Machaczka M, Paucar M, Bj\u00f6rkvall CK et al (2018) Novel hyperkinetic dystonia-like manifestation and neurological disease course of Swedish Gaucher patients. Blood Cells Mol Dis 68:86\u201392. https:\/\/doi.org\/10.1016\/j.bcmd.2016.10.011","journal-title":"Blood Cells Mol Dis"},{"key":"2493_CR62","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.jpeds.2007.12.023","volume":"153","author":"O Goker-Alpan","year":"2008","unstructured":"Goker-Alpan O, Wiggs EA, Eblan MJ et al (2008) Cognitive outcome in treated patients with chronic neuronopathic Gaucher disease. J Pediatr 153:89-94.e4. https:\/\/doi.org\/10.1016\/j.jpeds.2007.12.023","journal-title":"J Pediatr"},{"key":"2493_CR63","doi-asserted-by":"publisher","first-page":"e2272","DOI":"10.1212\/wnl.0000000000008618","volume":"93","author":"AM Steward","year":"2019","unstructured":"Steward AM, Wiggs E, Lindstrom T et al (2019) Variation in cognitive function over time in Gaucher disease type 3. Neurology 93:e2272\u2013e2283. https:\/\/doi.org\/10.1212\/wnl.0000000000008618","journal-title":"Neurology"},{"key":"2493_CR64","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/s10048-020-00607-4","volume":"21","author":"AAG Tantawy","year":"2020","unstructured":"Tantawy AAG, Adly AAM, Abdeen MSED, Salah NY (2020) Cognitive decline and depressive symptoms: early non-motor presentations of parkinsonism among Egyptian Gaucher patients. Neurogenetics 21:159\u2013167. https:\/\/doi.org\/10.1007\/s10048-020-00607-4","journal-title":"Neurogenetics"},{"key":"2493_CR65","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1007\/s10545-012-9460-7","volume":"35","author":"M Biegstraaten","year":"2012","unstructured":"Biegstraaten M, Wesnes KA, Luzy C et al (2012) The cognitive profile of type 1 Gaucher disease patients. J Inherit Metab Dis 35:1093\u20131099. https:\/\/doi.org\/10.1007\/s10545-012-9460-7","journal-title":"J Inherit Metab Dis"},{"key":"2493_CR66","doi-asserted-by":"publisher","first-page":"e158","DOI":"10.1212\/nxg.0000000000000158","volume":"3","author":"M Abdelwahab","year":"2017","unstructured":"Abdelwahab M, Potegal M, Shapiro EG, Nestrasil I (2017) Previously unrecognized behavioral phenotype in Gaucher disease type 3. Neurol Genet 3:e158. https:\/\/doi.org\/10.1212\/nxg.0000000000000158","journal-title":"Neurol Genet"},{"key":"2493_CR67","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1097\/01.gim.0000153666.23707.ba","volume":"7","author":"D Elstein","year":"2005","unstructured":"Elstein D, Guedalia J, Doniger GM et al (2005) Computerized cognitive testing in patients with type I Gaucher disease: effects of enzyme replacement and substrate reduction. Genet Med 7:124\u2013130. https:\/\/doi.org\/10.1097\/01.gim.0000153666.23707.ba","journal-title":"Genet Med"},{"key":"2493_CR68","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2318-3-4","author":"T Dwolatzky","year":"2003","unstructured":"Dwolatzky T, Whitehead V, Doniger G et al (2003) Validity of a novel computerized cognitive battery for mild cognitive impairment. BMC Geriatr. https:\/\/doi.org\/10.1186\/1471-2318-3-4","journal-title":"BMC Geriatr"},{"key":"2493_CR69","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/j.ymgme.2020.10.010","volume":"131","author":"CN Poffenberger","year":"2020","unstructured":"Poffenberger CN, Inati S, Tayebi N et al (2020) EEG abnormalities in patients with chronic neuronopathic Gaucher disease: a retrospective review. Mol Genet Metab 131:358\u2013363. https:\/\/doi.org\/10.1016\/j.ymgme.2020.10.010","journal-title":"Mol Genet Metab"},{"key":"2493_CR70","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1111\/j.1469-8749.2008.03172.x","volume":"51","author":"DW Dunn","year":"2009","unstructured":"Dunn DW, Austin JK, Perkins SM (2009) Prevalence of psychopathology in childhood epilepsy: categorical and dimensional measures. Dev Med Child Neurol 51:364\u2013372. https:\/\/doi.org\/10.1111\/j.1469-8749.2008.03172.x","journal-title":"Dev Med Child Neurol"},{"key":"2493_CR71","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1080\/17474086.2021.1908120","volume":"14","author":"S Revel-Vilk","year":"2021","unstructured":"Revel-Vilk S, Szer J, Zimran A (2021) Hematological manifestations and complications of Gaucher disease. Expert Rev Hematol 14:347\u2013354. https:\/\/doi.org\/10.1080\/17474086.2021.1908120","journal-title":"Expert Rev Hematol"},{"key":"2493_CR72","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/s1096-7192(03)00071-4","volume":"79","author":"N Tayebi","year":"2003","unstructured":"Tayebi N (2003) Gaucher disease with parkinsonian manifestations: does glucocerebrosidase deficiency contribute to a vulnerability to parkinsonism? Mol Genet Metab 79:104\u2013109. https:\/\/doi.org\/10.1016\/s1096-7192(03)00071-4","journal-title":"Mol Genet Metab"},{"key":"2493_CR73","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1056\/nejmoa0901281","volume":"361","author":"E Sidransky","year":"2009","unstructured":"Sidransky E, Nalls MA, Aasly JO et al (2009) Multicenter analysis of glucocerebrosidase mutations in Parkinson\u2019s disease. N Engl J Med 361:1651\u20131661. https:\/\/doi.org\/10.1056\/nejmoa0901281","journal-title":"N Engl J Med"},{"key":"2493_CR74","doi-asserted-by":"publisher","first-page":"5842","DOI":"10.3390\/ijms23105842","volume":"23","author":"ML Furderer","year":"2022","unstructured":"Furderer ML, Hertz E, Lopez GJ, Sidransky E (2022) Neuropathological features of Gaucher disease and Gaucher disease with parkinsonism. Int J Mol Sci 23:5842. https:\/\/doi.org\/10.3390\/ijms23105842","journal-title":"Int J Mol Sci"},{"key":"2493_CR75","doi-asserted-by":"publisher","first-page":"e523","DOI":"10.1212\/nxg.0000000000000523","volume":"6","author":"L Straniero","year":"2020","unstructured":"Straniero L, Asselta R, Bonvegna S et al (2020) The SPID-GBA study. Neurol Genet 6:e523. https:\/\/doi.org\/10.1212\/nxg.0000000000000523","journal-title":"Neurol Genet"},{"key":"2493_CR76","doi-asserted-by":"publisher","DOI":"10.3389\/fnmol.2018.00043","author":"Y Zhang","year":"2018","unstructured":"Zhang Y, Shu L, Sun Q et al (2018) Integrated genetic analysis of racial differences of common GBA variants in Parkinson\u2019s disease: a meta-analysis. Front Mol Neurosci. https:\/\/doi.org\/10.3389\/fnmol.2018.00043","journal-title":"Front Mol Neurosci"},{"key":"2493_CR77","doi-asserted-by":"publisher","first-page":"e348","DOI":"10.1212\/nxg.0000000000000348","volume":"5","author":"H Iwaki","year":"2019","unstructured":"Iwaki H, Blauwendraat C, Leonard HL et al (2019) Genetic risk of Parkinson disease and progression: neurology. Genetics 5:e348. https:\/\/doi.org\/10.1212\/nxg.0000000000000348","journal-title":"Genetics"},{"key":"2493_CR78","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1002\/mds.26593","volume":"31","author":"A G\u00e1mez-Valero","year":"2016","unstructured":"G\u00e1mez-Valero A, Prada-Dacasa P, Santos C et al (2016) GBA mutations are associated with earlier onset and male sex in dementia with lewy bodies. Mov Disord 31:1066\u20131070. https:\/\/doi.org\/10.1002\/mds.26593","journal-title":"Mov Disord"},{"key":"2493_CR79","doi-asserted-by":"publisher","first-page":"104856","DOI":"10.1016\/j.neubiorev.2022.104856","volume":"141","author":"S Gaubert","year":"2022","unstructured":"Gaubert S, Hourregue C, Mouton-Liger F et al (2022) Exploring the link between GBA1 mutations and dementia with lewy, bodies, a mini-review. Neurosci Biobehav Rev 141:104856. https:\/\/doi.org\/10.1016\/j.neubiorev.2022.104856","journal-title":"Neurosci Biobehav Rev"},{"key":"2493_CR80","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1001\/jamaneurol.2014.313","volume":"71","author":"RN Alcalay","year":"2014","unstructured":"Alcalay RN, Dinur T, Quinn T et al (2014) Comparison of Parkinson risk in ashkenazi jewish patients with Gaucher disease and GBA heterozygotes. JAMA Neurol 71:752. https:\/\/doi.org\/10.1001\/jamaneurol.2014.313","journal-title":"JAMA Neurol"},{"key":"2493_CR81","doi-asserted-by":"publisher","first-page":"2909","DOI":"10.1093\/brain\/awq198","volume":"133","author":"M Biegstraaten","year":"2010","unstructured":"Biegstraaten M, Mengel E, Mar\u00f3di L et al (2010) Peripheral neuropathy in adult type 1 Gaucher disease: a 2-year prospective observational study. Brain 133:2909\u20132919. https:\/\/doi.org\/10.1093\/brain\/awq198","journal-title":"Brain"},{"key":"2493_CR82","doi-asserted-by":"publisher","first-page":"8844","DOI":"10.3390\/ijms24108844","volume":"24","author":"MG Tullo","year":"2023","unstructured":"Tullo MG, Irelli EC, Caramia F et al (2023) The spectrum of neurological and sensory abnormalities in Gaucher disease patients: a multidisciplinary study (SENOPRO). Int J Mol Sci 24:8844. https:\/\/doi.org\/10.3390\/ijms24108844","journal-title":"Int J Mol Sci"},{"key":"2493_CR83","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1002\/mds.24945","volume":"27","author":"A McNeill","year":"2012","unstructured":"McNeill A, Duran R, Proukakis C et al (2012) Hyposmia and cognitive impairment in Gaucher disease patients and carriers. Mov Disord 27:526\u2013532. https:\/\/doi.org\/10.1002\/mds.24945","journal-title":"Mov Disord"},{"key":"2493_CR84","first-page":"99","volume":"12","author":"M Alaei","year":"2018","unstructured":"Alaei M, Jafari N, Rohani F et al (2018) Are there neurological symptoms in type 1 of Gaucher disease. Iran J Child Neurol 12:99\u2013106","journal-title":"Iran J Child Neurol"},{"key":"2493_CR85","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.bcmd.2014.05.007","volume":"53","author":"N-C Lee","year":"2014","unstructured":"Lee N-C, Chien Y-H, Wong S-L et al (2014) Outcome of early-treated type III Gaucher disease patients. Blood Cells Mol Dis 53:105\u2013109. https:\/\/doi.org\/10.1016\/j.bcmd.2014.05.007","journal-title":"Blood Cells Mol Dis"},{"key":"2493_CR86","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1002\/ajmg.a.61479","volume":"182","author":"GK Seehra","year":"2020","unstructured":"Seehra GK, Eghbali A, Sidransky E, FitzGibbon E (2020) White vitreous opacities in five patients with Gaucher disease type 3. Am J Med Genet A 182:808\u2013812. https:\/\/doi.org\/10.1002\/ajmg.a.61479","journal-title":"Am J Med Genet A"},{"key":"2493_CR87","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.tips.2004.01.004","volume":"25","author":"AH Futerman","year":"2004","unstructured":"Futerman AH, Sussman JL, Horowitz M et al (2004) New directions in the treatment of Gaucher disease. Trends Pharmacol Sci 25:147\u2013151. https:\/\/doi.org\/10.1016\/j.tips.2004.01.004","journal-title":"Trends Pharmacol Sci"},{"key":"2493_CR88","doi-asserted-by":"publisher","first-page":"441","DOI":"10.3390\/ijms18020441","volume":"18","author":"J Stirnemann","year":"2017","unstructured":"Stirnemann J, Belmatoug N, Camou F et al (2017) A review of Gaucher disease pathophysiology, clinical presentation and treatments. Int J Mol Sci 18:441. https:\/\/doi.org\/10.3390\/ijms18020441","journal-title":"Int J Mol Sci"},{"key":"2493_CR89","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/nrm1052","volume":"4","author":"L Ellgaard","year":"2003","unstructured":"Ellgaard L, Helenius A (2003) Quality control in the endoplasmic reticulum. Nat Rev Mol Cell Biol 4:181\u2013191. https:\/\/doi.org\/10.1038\/nrm1052","journal-title":"Nat Rev Mol Cell Biol"},{"key":"2493_CR90","doi-asserted-by":"publisher","first-page":"2387","DOI":"10.1093\/hmg\/ddi240","volume":"14","author":"I Ron","year":"2005","unstructured":"Ron I, Horowitz M (2005) ER retention and degradation as the molecular basis underlying Gaucher disease heterogeneity. Hum Mol Genet 14:2387\u20132398. https:\/\/doi.org\/10.1093\/hmg\/ddi240","journal-title":"Hum Mol Genet"},{"key":"2493_CR91","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1080\/14789450.2016.1174583","volume":"13","author":"O Jung","year":"2016","unstructured":"Jung O, Patnaik S, Marugan J et al (2016) Progress and potential of non-inhibitory small molecule chaperones for the treatment of Gaucher disease and its implications for Parkinson disease. Expert Rev Proteom 13:471\u2013479. https:\/\/doi.org\/10.1080\/14789450.2016.1174583","journal-title":"Expert Rev Proteom"},{"key":"2493_CR92","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.ejpn.2021.03.013","volume":"32","author":"DP Ramad\u017ea","year":"2021","unstructured":"Ramad\u017ea DP, Zeku\u0161i\u0107 M, \u017digman T et al (2021) Early initiation of ambroxol treatment diminishes neurological manifestations of type 3 Gaucher disease: a long-term outcome of two siblings. Eur J Paediatr Neurol 32:66\u201372. https:\/\/doi.org\/10.1016\/j.ejpn.2021.03.013","journal-title":"Eur J Paediatr Neurol"},{"key":"2493_CR93","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1038\/s41591-018-0106-7","volume":"24","author":"G Massaro","year":"2018","unstructured":"Massaro G, Mattar CNZ, Wong AMS et al (2018) Fetal gene therapy for neurodegenerative disease of infants. Nat Med 24:1317\u20131323. https:\/\/doi.org\/10.1038\/s41591-018-0106-7","journal-title":"Nat Med"},{"key":"2493_CR94","doi-asserted-by":"publisher","first-page":"101595","DOI":"10.1016\/j.scr.2019.101595","volume":"41","author":"AJ Duarte","year":"2019","unstructured":"Duarte AJ, Ribeiro D, Santos R et al (2019) Induced pluripotent stem cell line (INSAi001-A) from a Gaucher disease type 3 patient compound heterozygote for mutations in the GBA1 gene. Stem Cell Res 41:101595. https:\/\/doi.org\/10.1016\/j.scr.2019.101595","journal-title":"Stem Cell Res"},{"key":"2493_CR95","doi-asserted-by":"publisher","first-page":"61","DOI":"10.3109\/08880018.2012.762076","volume":"30","author":"S Ito","year":"2013","unstructured":"Ito S, Barrett AJ (2013) Gauchers disease\u2014a reappraisal of hematopoietic stem cell transplantation. Pediatr Hematol Oncol 30:61\u201370. https:\/\/doi.org\/10.3109\/08880018.2012.762076","journal-title":"Pediatr Hematol Oncol"},{"key":"2493_CR96","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.cd006974.pub4","author":"URR Somaraju","year":"2017","unstructured":"Somaraju URR, Tadepalli K (2017) Hematopoietic stem cell transplantation for Gaucher disease. Cochrane Database Syst Rev. https:\/\/doi.org\/10.1002\/14651858.cd006974.pub4","journal-title":"Cochrane Database Syst Rev"},{"key":"2493_CR97","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-022-02378-7","author":"A Donald","year":"2022","unstructured":"Donald A, Bj\u00f6rkvall CK, Vellodi A et al (2022) Thirty-year clinical outcomes after haematopoietic stem cell transplantation in neuronopathic Gaucher disease. Orphanet J Rare Dis. https:\/\/doi.org\/10.1186\/s13023-022-02378-7","journal-title":"Orphanet J Rare Dis"},{"key":"2493_CR98","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.bcmd.2012.09.008","volume":"50","author":"D Elstein","year":"2013","unstructured":"Elstein D, Abrahamov A, Altarescu G, Zimran A (2013) Evolving features in type 3 Gaucher disease on long-term enzyme replacement therapy. Blood Cell Mol Dis 50:140. https:\/\/doi.org\/10.1016\/j.bcmd.2012.09.008","journal-title":"Blood Cell Mol Dis"}],"container-title":["Acta Neurologica Belgica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13760-024-02493-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13760-024-02493-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13760-024-02493-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,24]],"date-time":"2024-07-24T02:43:58Z","timestamp":1721789038000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13760-024-02493-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,28]]},"references-count":98,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["2493"],"URL":"https:\/\/doi.org\/10.1007\/s13760-024-02493-1","relation":{},"ISSN":["0300-9009","2240-2993"],"issn-type":[{"value":"0300-9009","type":"print"},{"value":"2240-2993","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,28]]},"assertion":[{"value":"7 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 February 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}